1.Erratum: Mutation Analysis of SPAST, ATL1, and REEP1 in Korean Patients with Hereditary Spastic Paraplegia.
Tae Hyoung KIM ; Jae Hyeok LEE ; Young Eun PARK ; Jin Hong SHIN ; Tai Seung NAM ; Hyang Sook KIM ; Ho Jung JANG ; Artem SEMENOV ; Sang Jin KIM ; Dae Seong KIM
Journal of Clinical Neurology 2014;10(4):376-376
The publisher wishes to apologize for incorrectly displaying Fig. 1 and its legend.
2.Erratum: Depression and Anxiety in People with Epilepsy.
Journal of Clinical Neurology 2014;10(4):375-375
The Korean version of Neurological Disorders Depression Inventory for Epilepsy in Table 3 was inadvertently omitted from the original publication of this article.
3.Somatosensory Conduction Pathway in Spastic Paraplegia Type 5.
Alessandra VANOTTI ; Lorenzo NANETTI ; Davide ROSSI SEBASTIANO ; Elisa VISANI ; Dunja DURAN ; Daniela DI BELLA ; Elisa SARTO ; Claudio CACCIA ; Valerio LEONI ; Franco TARONI ; Caterina MARIOTTI
Journal of Clinical Neurology 2014;10(4):373-374
No abstract available.
Paraplegia*
4.Does Hereditary Neuropathy with Liability to Pressure Palsy Predispose to Schwannomatosis?.
Aude Marie GRAPPERON ; Jerome FRANQUES ; Pierre Hugues ROCHE ; Fabrice BATTAGLIA
Journal of Clinical Neurology 2014;10(4):371-372
No abstract available.
Paralysis*
5.Saccadic Palsy after Cardiac Surgery: Serial Neuroimaging Findings during a 6-Year Follow-Up.
Eun Joo KIM ; Kwang Dong CHOI ; Jeong Eun KIM ; Seong Jang KIM ; Ji Soo KIM ; Jong S KIM ; Jee Hyang JEONG
Journal of Clinical Neurology 2014;10(4):367-370
BACKGROUND: Patients who develop horizontal and vertical saccadic palsy after cardiac surgery have rarely been described. Although most such patients exhibit distinct neurological deficits, their brain MRI findings are almost normal. In addition, functional neuroimaging of such patients has never been reported. CASE REPORT: A 43-year-old woman with dysarthria, dysphagia, and horizontal and vertical saccadic palsy after cardiac surgery was followed up for about 6 years; serial brain MRIs has been performed during this period, including susceptibility-weighted imaging (SWI) and [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET). Multiple microbleeds in the cerebral cortex, cerebellum, and brainstem, and glucose hypometabolism in the brainstem, cerebellum, and multiple cortical areas. CONCLUSIONS: To the best of our knowledge, this is the first reported case of saccadic palsy after cardiac surgery with serial SWI and [18F]-FDG-PET performed to explore the possible cerebral lesions.
Adult
;
Brain
;
Brain Stem
;
Cerebellum
;
Cerebral Cortex
;
Deglutition Disorders
;
Dysarthria
;
Female
;
Follow-Up Studies*
;
Functional Neuroimaging
;
Glucose
;
Humans
;
Magnetic Resonance Imaging
;
Neuroimaging*
;
Paralysis*
;
Positron-Emission Tomography
;
Saccades
;
Thoracic Surgery*
6.Hydrocephalus and Neurocysticercosis: Cases Illustrative of Three Distinct Mechanisms.
Aymeric AMELOT ; Thierry FAILLOT
Journal of Clinical Neurology 2014;10(4):363-366
BACKGROUND: Cysticercosis is the most frequent parasitic infection of the nervous system. Most lesions are intracranial, and spinal involvement is rare. We describe here in two cases of neurocysticercosis (NCC) in the brain and one in the spinal cord that illustrate three distinct mechanisms leading to symptomatic acute hydrocephalus. CASE REPORT: Hydrocephalus was related to intracranial NCC in two of them. In the first case the hydrocephalus was due to an extensive arachnoiditis to the craniocervical junction, while in the second it was caused by obstruction of Magendie's foramen in the fourth ventricle by the scolex of Taenia solium. For the third patient, hydrocephalus revealed cysticercosis of the cauda equina due to the scolex. CONCLUSIONS: NCC should be considered as a possible diagnosis for patients suffering from hydrocephalus when they originate from or have traveled in endemic areas, MRI of the spine is mandatory to search for intraspinal lesions.
Arachnoid
;
Arachnoiditis
;
Brain
;
Cauda Equina
;
Cysticercosis
;
Diagnosis
;
Fourth Ventricle
;
Humans
;
Hydrocephalus*
;
Magnetic Resonance Imaging
;
Nervous System
;
Neurocysticercosis*
;
Spinal Cord
;
Spine
;
Taenia solium
7.Drastic Therapy for Listerial Brain Abscess Involving Combined Hyperbaric Oxygen Therapy and Antimicrobial Agents.
Keiichi NAKAHARA ; Satoshi YAMASHITA ; Katsumasa IDEO ; Seigo SHINDO ; Tomohiro SUGA ; Akihiko UEDA ; Shoji HONDA ; Tomoo HIRAHARA ; Masaki WATANABE ; Taro YAMASHITA ; Yasushi MAEDA ; Yasuhiro YONEMOCHI ; Tomohiro TAKITA ; Yukio ANDO
Journal of Clinical Neurology 2014;10(4):358-362
BACKGROUND: Listeria monocytogenes (L. monocytogenes) is a rare causative pathogen of brain abscess that is often found in immunocompromised patients. Although patients with supratentorial listerial abscesses showed a longer survival with surgical drainage, the standard therapy for patients with subtentorial lesions has not been established. CASE REPORT: We report herein a patient with supra- and subtentorial brain abscesses caused by L. monocytogenes infection. These abscesses did not respond to antibiotics, and his symptoms gradually worsened. Drainage was not indicated for subtentorial lesions, and the patient was additionally treated with hyperbaric oxygen therapy, which dramatically reduced the volume of abscesses and improved the symptoms. CONCLUSIONS: This is the first report of drastic therapy for a patient with listerial brain abscesses involving combined antibiotics and hyperbaric oxygen therapy. The findings suggest that hyperbaric oxygen therapy is a good option for treating patients with deep-seated listerial abscesses and for who surgical drainage is not indicated.
Abscess
;
Anti-Bacterial Agents
;
Anti-Infective Agents*
;
Brain Abscess*
;
Drainage
;
Humans
;
Hyperbaric Oxygenation*
;
Immunocompromised Host
;
Listeria monocytogenes
8.Fulminant Subacute Sclerosing Panencephalitis Presenting with Acute Ataxia and Hemiparesis in a 15-Year-Old Boy.
Rukmini Mridula KANDADAI ; Praveen YADA ; Megha S UPPIN ; Shaik Afshan JABEEN ; Ajith CHERIAN ; Meena Angamuthu KANIKANNAN ; Rupam BORGOHAIN ; Sundaram CHALLA
Journal of Clinical Neurology 2014;10(4):354-357
BACKGROUND: Subacute sclerosing panencephalitis (SSPE) is a delayed and fatal manifestation of measles infection. Fulminant SSPE is a rare presentation in which the disease progresses to death over a period of 6 months. The clinical features are atypical and can be misleading. CASE REPORT: We report herein a teenage boy who presented with acute-onset gait ataxia followed by right hemiparesis that evolved over 1 month, with left-hemispheric, delta-range slowing on the electroencephalogram (EEG). Magnetic resonance imaging disclosed multiple white-matter hyperintensities, suggesting a diagnosis of acute disseminated encephalomyelitis. He received intravenous steroids, and within 4 days of hospital admission he developed unilateral slow myoclonic jerks. Repeat EEG revealed Rademecker complexes, pathognomonic of SSPE, and an elevated titer of IgG antimeasles antibodies was detected in his cerebrospinal fluid. The disease progressed rapidly and the patient succumbed within 15 days of hospitalization. The diagnosis of SSPE was confirmed by autopsy. CONCLUSIONS: This case illustrates the difficulty of recognizing fulminant SSPE when it manifests with asymmetric clinical and EEG abnormalities.
Adolescent*
;
Antibodies
;
Ataxia*
;
Autopsy
;
Cerebrospinal Fluid
;
Diagnosis
;
Electroencephalography
;
Encephalomyelitis, Acute Disseminated
;
Gait Ataxia
;
Hospitalization
;
Humans
;
Immunoglobulin G
;
Magnetic Resonance Imaging
;
Male
;
Measles
;
Myoclonus
;
Paresis*
;
Steroids
;
Subacute Sclerosing Panencephalitis*
9.Correlation between Ultrasonography Findings and Electrodiagnostic Severity in Carpal Tunnel Syndrome: 3D Ultrasonography.
Hee Kyu KWON ; Hyo Jung KANG ; Chan Woo BYUN ; Joon Shik YOON ; Chang Ho KANG ; Sung Bum PYUN
Journal of Clinical Neurology 2014;10(4):348-353
BACKGROUND AND PURPOSE: To determine the correlation between the cross-sectional area (CSA) of the median nerve measured at the wrist using three-dimensional (3D) ultrasonography (US) and the electrophysiological severity of carpal tunnel syndrome (CTS). METHODS: We prospectively examined 102 wrists of 51 patients with clinical CTS, which were classified into 3 groups according to the electrodiagnostic (EDX) findings. Median nerve CSAs were measured using 3D US at the carpal tunnel inlet and at the level of maximal swelling. RESULTS: Ten wrists were negative for CTS. Of the 92 CTS-positive wrists, 23, 30, and 39 were classified as having mild, moderate, and severe CTS, respectively. The median nerve CSA differed significantly between the severe- and moderate-CTS groups (p=0.0007 at the carpal tunnel inlet and p<0.0001 at the maximal swelling site). There was a correlation between median nerve CSA and EDX parameters among those wrists with severe and mild CTS (p<0.0001 at both sites). CONCLUSIONS: The median nerve CSA as measured by 3D US could provide additional information about the severity of CTS, as indicated by the strong correlation with standard EDX findings.
Bays
;
Carpal Tunnel Syndrome*
;
Humans
;
Median Nerve
;
Prospective Studies
;
Ultrasonography*
;
Wrist
10.Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility.
Hyun Young KIM ; Chanil MOON ; Kyung Suk KIM ; Ki Wook OH ; Seong Il OH ; Juhan KIM ; Seung Hyun KIM
Journal of Clinical Neurology 2014;10(4):342-347
BACKGROUND AND PURPOSE: It has been shown that erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients. METHODS: Two consecutive studies were conducted. We first recruited 26 subjects for an initial single-arm safety study. After a lead-in period of 3 months to assess the disease progression, rhEPO was infused intravenously (35,000 IU) once per month for 3 months, and the subjects were followed for an additional 3 months. The ALS Functional Rating Scale-Revised (ALSFRS-R) was used for clinical assessment. After confirming the safety of rhEPO, 60 subjects were recruited for the second controlled study (rhEPO and control groups), which involved a total of 6 infusions at a rate of 1/month. RESULTS: There were no serious adverse events in the first study. The mean rate of decline in the ALSFRS-R score was lower during the treatment period than during the lead-in period (mean+/-SD: 2.6+/-1.8 and 3.7+/-2.6, respectively; p=0.02). However, the rate of decline during the subsequent 3 months returned to that observed in the lead-in period. In the second study, the mean rate of decline in ALSFRS-R score was significantly lower in the rhEPO group than in the control group (during months 0-3, 1.8+/-1.7 vs. 3.1+/-2.3, p=0.03; during months 4-6, 2.1+/-2.2 vs. 3.5+/-2.3, p=0.02). CONCLUSIONS: Intravenous high-dose rhEPO is both safe and feasible for the treatment of ALS. Further investigation using different intervals and doses should be considered.
Amyotrophic Lateral Sclerosis*
;
Disease Progression
;
Erythropoietin*
;
Humans
;
Models, Animal
;
Neurodegenerative Diseases
;
Pilot Projects*